Filgotinib, an investigational and selective JAK1 inhibitor, has achieved its primary efficacy endpoint in adults with moderately to severely active AS in the phase 2 Tortuga study. AS
Imprime PGG is an innate immune trigger that activates anti-cancer T cells. Durvalumab is a human monocolonal antibody that blocks the immune checkpoint protein, programmed death-ligand (PD-L1), and
Under the agreement, Aurobindo will purchase Sandoz US dermatology business and generic US oral solids portfolio. As part of the deal, Aurobindo will acquire manufacturing facilities in Wilson
Redx will now work with the investigators to finalize this protocol, with the intention of restarting dosing of patients in the first half of 2019. Based on a
Merkel cell carcinoma is a rare form of skin cancer caused by a Merkel cell associated polyomavirus. The company’s supplemental biologics license application (sBLA), which has been accepted
Over this period, CHDI may fund up to 75 full-time scientists at Evotec. The collaboration was initiated in 2006 and has grown considerably over this period to fully
Cablivi is claimed to be the first therapeutic specifically developed to treat aTTP, a rare blood-clotting disorder. The approval was based on data from the phase II Titan
The initial recommended prophylactic regimen for Jivi is twice weekly with the ability to dose every five days and further individually adjust to less or more frequent dosing
AstraZeneca, along with its global biologics research and development arm MedImmune, has reported the top-line results from the Tulip 1 phase III trial for anifrolumab in adult patients
The original contract in Alzheimer’s disease was announced on 5 July 2017 and this change order reflects an extension of the contract term from September 2020 to May
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.